Please provide your email address to receive an email when new articles are posted on . Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to ...

Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years. DDLPS ...

Please provide your email address to receive an email when new articles are posted on . Administration of the MDM2 inhibitor milademetan in an intermittent dosing schedule mitigated dose-limiting ...

Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full ...

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST) SEAL was a phase II-III, multicenter, ...

Storm clouds are brewing for Rain Oncology after its lead asset failed to improve progression-free survival (PFS) versus chemotherapy in a phase 3 trial of patients with liposarcoma. Rain’s shares ...

Rain Oncology is a late-stage oncology company. Their lead product, milademetan, is an oral inhibitor of the MDM2-p53. In the past, MDM2 inhibitors have been associated with severe hematologic events.

NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, ...

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...

Esophageal liposarcoma and fibrovascular polyps represent rare but clinically significant tumours of the oesophagus. Traditionally, fibrovascular polyps have been considered benign, pedunculated ...